Patent protection for medicinal products – the negative aspects, alternatives
Keywords:
health economics, intellectual property, patents, medications, drugsAbstract
Patent protection of pharmaceutical products is exceptio-nally extensive and results from a specific nature of goods to which it relates. Application of intellectual property rights protection is justified in this case by arguments based on rule of justice and positive results of patent protection. However the negative effects of intellectual property protection (including deceptive innovations, social costs related to monopoly position of patent bearing company, social costs related to temporary limitation of free use of new ideas and technologies, more difficult access to medications in deve-loping countries) make it necessary to consider solutions alternative to the existing patent system. This thesis provides a review and evaluation of the above solutions as far as possibilities of their implementation and elimination of problems with medication manufacturing and accessibility are concerned. Implications to modification of the existing patent system resulting from the carried out solution analysis are a summary of the thesis.
References
1. Mickiewicz G. Leki innowacyjne. Służba Zdrowia. 2009;18-21:39.
2. The Trade Related Aspects of Intellectual Property Rights. WTO; Marrakesh 1994.
3. Nędzi K. Ochrona własności intelektualnej w przemyśle farmaceutycznym i jej społeczne implikacje. W: Ryć K, Skrzypczak Z. Ochrona zdrowia i gospodarka. Warszawa: Wydawnictwo Naukowe Wydziału Zarządzania Uniwersytetu Warszawskiego 2008. s. 291-5.
4. Dietsch P. Patents on Drugs - the Wrong Prescription. W: Gosseries A, Marciano A, Strowel A. Intellectual property and theories of justice. Palgrave Macmillan: Houndmills 2008.s. 232-42.
5. Belleflamme P. Patents and incentives to innovate some theorethical and empirical economic evidence. Ethical Perspectives. 2006;13(2):268-71.
6. Walley T, Haycox A, Boland A. Pharmacoeconomies. Edinburgh: Churchill Livingstone 2004.s.18-22.
7. Belleflamme P. The Patent System and the Pharmaceutical Sector. W: Gosseries A, Marciano A, Strowel A. Intellectual property and theories of justice. Palgrave Macmillan: Houndmills 2008.s.222-4.
8. Barton JH, Emanuel EJ. The Patents-Based Pharmaceutical Development Process: Rationale, Problems, and Potential Reforms. JAMA. 2005;294:2075-82.
9. Pogge TW. Human Rights and Global Health: a Research Program. Metaphilosophy. 2005;36:182-209.
10. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002; 359:2192-3.
11. Begg D, Fischer S, Dornbush R. Mikroekonomia. Warszawa: Polskie Wydawnictwo Ekonomiczne 2007.s.524.
12. Mahoney RT. Public-private partnership in the development of the hepatitis B vaccine in Korea: implications for developing countries. Sci Tech Soc. 2005;10:129-40.
13. Kuanpoth J. Intellectual property and access to essential medicines: options for developing countries. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 2004;2:53-62.
14. Smythe KF. Development and analysis of a public-private partnership: Implications for practice. James Madison University; 2004.s.4-6.
15. Bovis Ch. Public-Public Partnerships versus Public Private Partnerships: Conceptual and Regulatory Issues European Public Private Partnership Law Review 2010;5(4):197-9.